uniQure (NASDAQ: QURE) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We spoke with uniQure following our recent assumption of coverage of the company’s stock and ahead of the upcoming, highly anticipated initial data readout from AMT-130 Phase I/II trial in four Huntington’s disease patients, expected by YE21. We believe investor expectations are very low and see a favorable risk/reward for the stock going into this data. That said, we remain cautious given the small sample size and limited follow-up on the biomarker data which could make it hard for investors to gain greater conviction in AMT-130 at this point. We provide our thoughts below.”
To request access to the full report, visit http://nnw.fm/SaZ9d
About uniQure N.V.
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The company is leveraging its modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington’s disease, Fabry disease, spinocerebellar ataxia Type 3 temporal lobe epilepsy, Alzheimer’s, Parkinson’s and ALS. For more information, visit the company’s website at www.uniQure.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
